Chapter Locator/HTC

The CDC supports a network of specialized healthcare centers to prevent and reduce complications experienced by persons with certain blood disorders including hemophilia A, hemophilia B, and von Willebrand disease.

The Hemophilia Foundation has created The Chapter Center with information regarding the Chapter nearest you.

Find a CSL Behring representative near you. More>>

Helixatefs.com

Important Safety Information for Helixate^®FS

Helixate^® FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor.

Helixate^® FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations of known sensitivity to mouse or hamster protein.

Adverse events are generally minor. The most common adverse events include injection-site reactions, dizziness, and rash.

For more information about Helixate^® FS, please see full Prescribing Information.